BonesLabsBlog
Back to all posts
Uncategorized

Semaglutide

Semaglutide: A Long-Acting GLP-1 Receptor Agonist

Research summary. Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1), engineered for once-weekly subcutaneous administration through a combination of amino-acid substitutions and a C18 fatty-acid acylation chain that supports albumin binding. Developed by Novo Nordisk, it is approved by the U.S. Food and Drug Administration for type 2 diabetes (under the brand name Ozempic) and for chronic weight management (as Wegovy), and is also available as an oral tablet (Rybelsus) using a permeation-enhancer formulation. It is one of the most clinically validated peptide therapeutics of the past decade.

Molecular profile

  • Class: Long-acting GLP-1 receptor agonist
  • Sequence: Modified human GLP-1(7–37) backbone with substitutions at positions 8 (Aib for Ala), 34 (Arg for Lys), and a γ-Glu-2×OEG-C18 di-acid attachment at Lys26
  • Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉
  • Molecular weight: ~4113.6 g/mol
  • PubChem CID: 56843331
  • CAS Number: 910463-68-2
  • Brand names: Ozempic, Wegovy, Rybelsus (oral)
  • Half-life: ~7 days (subcutaneous)

The Aib substitution at position 8 prevents DPP-IV cleavage, the C18 di-acid linker confers albumin binding, and the additional substitutions support physical stability at the formulation pH. Together these modifications give semaglutide a half-life of approximately one week — sufficient for once-weekly dosing.

Mechanism of action

Semaglutide is a full agonist at the GLP-1 receptor (GLP-1R), a class B GPCR expressed on pancreatic beta cells, neurons in hypothalamic and brainstem feeding circuits, gastric smooth muscle, and other tissues. Receptor activation produces:

  • Glucose-dependent insulin secretion from pancreatic beta cells, supporting post-prandial glycaemia
  • Suppression of glucagon secretion under hyperglycaemic conditions
  • Slowing of gastric emptying, contributing to post-prandial glucose smoothing
  • Activation of central satiety circuits in the hypothalamus and brainstem, reducing food intake
  • Beta-cell preservation through anti-apoptotic signalling
  • Cardiovascular benefits mediated through endothelial, cardiac, and metabolic effects, partially independent of glucose lowering

The glucose-dependence of insulin secretion is critical: GLP-1R agonism does not provoke hypoglycaemia in normoglycaemic conditions, distinguishing it from sulfonylureas and direct insulin therapy.

Clinical research highlights

Cardiovascular outcomes (SUSTAIN-6). A landmark trial in type 2 diabetes (Marso et al., 2016) reported that semaglutide reduced major adverse cardiovascular events compared with placebo, establishing the molecule's cardiovascular benefit profile [1].

Weight management (STEP programme). The STEP-1 trial (Wilding et al., 2021) reported approximately 15% mean body-weight reduction at 68 weeks with semaglutide 2.4 mg weekly versus approximately 2.4% with placebo in adults with overweight or obesity without diabetes [2]. Subsequent STEP trials confirmed the effect across multiple populations, including adolescents.

Cardiovascular outcomes in obesity (SELECT). A trial in adults with overweight or obesity and established cardiovascular disease (without diabetes) reported reductions in major adverse cardiovascular events with semaglutide compared with placebo, extending its cardiovascular benefit profile beyond the diabetic population.

Heart failure (STEP-HFpEF). A trial in patients with heart failure with preserved ejection fraction and obesity reported improvements in symptoms, body weight, and 6-minute walk distance with semaglutide.

Renal outcomes (FLOW). A trial in type 2 diabetes with chronic kidney disease reported reductions in renal-event composites and mortality.

Oral semaglutide (PIONEER programme). Studies of the SNAC-permeation-enhancer oral formulation have established efficacy for glycaemic control comparable to injectable GLP-1 receptor agonists, with reduced absolute bioavailability (~1%) but pharmacologically meaningful systemic exposure with daily dosing.

Position in the GLP-1 landscape

Semaglutide is part of a broader class of GLP-1 receptor agonists that has evolved over two decades:

  • Exenatide: First-generation, twice-daily, derived from exendin-4 (Gila monster venom)
  • Liraglutide (Victoza/Saxenda): Once-daily, fatty-acid acylated GLP-1 analogue
  • Dulaglutide (Trulicity): Once-weekly Fc-fusion GLP-1
  • Semaglutide: Once-weekly with substantial weight-loss efficacy
  • Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist, generally producing greater weight loss than semaglutide in head-to-head studies
  • Retatrutide: Triple GIP/GLP-1/glucagon agonist in Phase 3

Semaglutide remains a reference compound across this landscape and the most extensively clinically characterised member of the class.

Current status

Semaglutide is FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and for chronic weight management (Wegovy). It is one of the few peptides included in this catalogue that has full regulatory approval across multiple jurisdictions. It is widely studied as both a clinical therapeutic and a research tool for GLP-1R biology in metabolic, cardiovascular, renal, and neurological contexts.

Key takeaways for researchers

  • Semaglutide is a long-acting GLP-1 receptor agonist with weekly subcutaneous and daily oral formulations.
  • It is FDA-approved for type 2 diabetes and chronic weight management.
  • Key clinical evidence comes from the SUSTAIN, STEP, SELECT, FLOW, and PIONEER trial programmes.
  • Reported activity spans glycaemic control, weight management, cardiovascular outcomes, renal outcomes, and heart failure.
  • Semaglutide represents a benchmark for clinical-stage GLP-1 receptor pharmacology.

References

  1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834–1844.
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002.

This article is provided for educational and research purposes only. While semaglutide is FDA-approved for specific clinical indications under the brand names Ozempic, Wegovy, and Rybelsus, research-grade semaglutide supplied through research-peptide channels is not equivalent to a prescribed pharmaceutical and is not intended for human consumption. Approved use of semaglutide should occur only under the direction of a qualified clinician and within an authorised supply chain. Research work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

Semaglutide | BonesLabs